Literature DB >> 16720757

alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine.

Mirko Moroni1, Ruud Zwart, Emanuele Sher, Bruce K Cassels, Isabel Bermudez.   

Abstract

alpha4 and beta2 nicotinic acetylcholine receptor (nAChR) subunits expressed heterologously assemble into receptors with high (HS) and low (LS) sensitivity to acetylcholine (ACh); their relative proportions depend on the alpha4to beta2 ratio. In this study, injection of oocytes with 1:10 alpha4/beta2 subunit cDNA ratios favored expression of HS alpha4beta2 nAChRs, as evidenced by monophasic ACh concentration-response curves, whereas injections with 10:1 cDNA ratios favored expression of LS alpha4beta2 receptors. The stoichiometry was inferred from the shifts in the ACh EC(50) values caused by Leu to Thr mutations at position 9' of the second transmembrane domain of alpha4 and beta2. The 1:10 injection ratio produced the (alpha4)(2)(beta2)(3) stoichiometry, whereas 10:1 injections produced the (alpha4)(3)(beta2)(2) stoichiometry. The agonists epibatidine, 3-[2(S)-azetidinylmethoxy]pyridine (A-85380), 5-ethoxy-metanicotine (TC-2559), cytisine, and 3-Br-cytisine and the antagonists dihydro-beta-erythroidine and d-tubocurarine were more potent at HS receptors. TC-2559 was more efficacious than ACh at HS receptors but was a partial agonist at LS receptors. Epibatidine was more efficacious than ACh at LS receptors and a partial agonist at HS receptors. Cytisine and 5-halogenated cytisines had moderate efficacy at LS receptors but had almost no efficacy at HS receptors. By exploiting the differential effects of ACh, TC-2559 and 5-I-cytisine we evaluated the effects of long-term exposure to nicotine on HS and LS receptors expressed in Xenopus laevis oocytes after cDNA injections or microtransplantation of alpha4beta2 receptors assembled in human embryonic kidney 293 cells. We conclude that nicotine up-regulates HS alpha4beta2 receptors, probably by influencing the assembly of receptors rather than by altering the functional state of LS alpha4beta2 nAChRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720757     DOI: 10.1124/mol.106.023044

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  133 in total

1.  Live-cell imaging of single receptor composition using zero-mode waveguide nanostructures.

Authors:  Christopher I Richards; Khai Luong; Rahul Srinivasan; Stephen W Turner; Dennis A Dougherty; Jonas Korlach; Henry A Lester
Journal:  Nano Lett       Date:  2012-06-08       Impact factor: 11.189

Review 2.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.

Authors:  Maegan M Weltzin; Yanzhou Huang; Marvin K Schulte
Journal:  Eur J Pharmacol       Date:  2012-06-23       Impact factor: 4.432

5.  Alpha-conotoxin AuIB isomers exhibit distinct inhibitory mechanisms and differential sensitivity to stoichiometry of alpha3beta4 nicotinic acetylcholine receptors.

Authors:  Anton A Grishin; Ching-I A Wang; Markus Muttenthaler; Paul F Alewood; Richard J Lewis; David J Adams
Journal:  J Biol Chem       Date:  2010-05-13       Impact factor: 5.157

6.  The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy.

Authors:  Craig D C Bailey; Mariella De Biasi; Paul J Fletcher; Evelyn K Lambe
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

Review 7.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

8.  Identifying the binding site of novel methyllycaconitine (MLA) analogs at α4β2 nicotinic acetylcholine receptors.

Authors:  Gracia X J Quek; Diana Lin; Jill I Halliday; Nathan Absalom; Joseph I Ambrus; Andrew J Thompson; Martin Lochner; Sarah C R Lummis; Malcolm D McLeod; Mary Chebib
Journal:  ACS Chem Neurosci       Date:  2010-10-07       Impact factor: 4.418

9.  Potentiation of a neuronal nicotinic receptor via pseudo-agonist site.

Authors:  Simone Mazzaferro; Isabel Bermudez; Steven M Sine
Journal:  Cell Mol Life Sci       Date:  2019-01-01       Impact factor: 9.261

10.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.